ReviewDrugs2015
Recombinant Human Parathyroid Hormone (1-84): A Review in Hypoparathyroidism.
Review in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 36 citations in OpenAlex.
- Advancing hypoparathyroidism treatment: FDA approval of Palopegteriparatide as a promising orphan drug.Annals of medicine and surgery (2012) · 2026Article
- Ultrasound combined with serum parathyroid hormone for assessing autologous parathyroid graft viability after endoscopic thyroidectomy: a retrospective study.Frontiers in endocrinology · 2026Article
- A novel chromatography method for high purity production of Recombinant human parathyroid hormone from E. coli.Scientific reports · 2025Article
- Progress and future prospects for the surgical treatment of permanent hypoparathyroidism after thyroid surgery: a narrative review.BMC surgery · 2025Review
- Escherichia coli in the production of biopharmaceuticals.Biotechnology and applied biochemistry · 2025Review
- Backbone Modification Provides a Long-Acting Inverse Agonist of Pathogenic, Constitutively Active PTH1R Variants.Journal of the American Chemical Society · 2024Article
- Altered signaling at the PTH receptor via modified agonist contacts with the extracellular domain provides a path to prolonged agonism in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Trends in peptide drug discovery.Nature reviews. Drug discovery · 2021Article
- Intermittent Bi-Daily Sub-cutaneous Teriparatide Administration in Children With Hypoparathyroidism: A Single-Center Experience.Frontiers in pediatrics · 2021Article
- Current treatment of hypoparathyroidism: Theory versus reality waiting guidelines for children and adolescents.Acta bio-medica : Atenei Parmensis · 2018Review
- Recombinant Parathyroid Hormone Versus Usual Care: Do the Outcomes Justify the Cost?World journal of surgery · 2018Article
- Short and long-term impact of parathyroid autotransplantation on parathyroid function after total thyroidectomy.Gland surgery · 2017Review
- Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism.Nature communications · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Full-length recombinant human parathyroid hormone [rhPTH (1-84); Natpara(®)] is approved in the USA as an adjunct to calcium and vitamin D therapy for control of hypocalcaemia in patients with hypoparathyroidism. This article reviews the clinical efficacy and tolerability of rhPTH (1-84) in hypoparathyroidism and summarizes its pharmacological properties. In a pivotal phase III trial, subcutaneous rhPTH (1-84) was effective in maintaining albumin-corrected total serum calcium levels while reducing/eliminating the need for oral calcium and active vitamin D. rhPTH (1-84) had a generally acceptable tolerability profile in this trial, with <3% of patients discontinuing treatment because of adverse events. Commonly occurring adverse reactions included hypocalcaemia, hypercalcaemia and hypercalciuria. As the first PTH replacement therapy for hypoparathyroid patients with hypocalcaemia, rhPTH (1-84) is an effective regimen, has generally acceptable tolerability and represents an important advance for the management of hypoparathyroidism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.